Document is current

Article History

Received: 5 June 2020

Accepted: 8 December 2020

First Online: 5 January 2021

Compliance with ethical standards

:

: The authors disclose the following associations: Toshimitsu Fujii received a research grants/clinical trial funding from AbbVie, Boehringer Ingelheim, Celgene, EA Pharma, Eisai, Gilead Sciences, and Eli Lilly. TF serves as speaker’s bureau for AbbVie, Ajinomoto Pharma, Boehringer Ingelheim, Daiichi Sankyo, EA Pharma, Kyorin Pharma, Kyowa Hakko Kirin, BMS, Nichiiko, Kyorin, Nippon Kayaku, Kissei Pharma, Zeria Pharma, and Janssen Pharma. Mamoru Watanabe received research grants/clinical trial funding from AbbVie, Boehringer Ingelheim, Celgene, EA Pharma, Eisai, Gilead Sciences, Eli Lilly, and Mitsubishi Tanabe Pharma. MW serves as speaker’s bureau for Ajinomoto Pharma, Kyorin Pharma, Mitsubishi Tanabe Pharma, Kyorin, Mochida Pharma, Nippon Kayaku, and Janssen Pharma. Masakazu Nagahori serves as a consultant to Kissei Pharma and Takeda. MN serves as speaker’s bureau for AbbVie, Mitsubishi Tanabe Pharma, Kyorin, Nippon Kayaku, Kissei Pharma, Asashi Kasei, Zeria Pharma, Astellas Pharma, and Janssen Pharma. Kazuo Ohtsuka serves as speaker’s bureau for AbbVie, Mitsubishi Tanabe Pharma, Kyorin, Mochida Pharma, and Zeria Pharma. Kento Takenaka serves as speaker’s bureau for Mitsubishi Tanabe Pharma, Kyorin, Mochida Pharma, and Zeria Pharma. The remaining authors have no conflicts to disclose.

: All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

: Informed consent was obtained from the patient for being included in the study.